吉西他滨联合化疗在晚期胰腺癌治疗中的作用探讨

Effect of Gemcitabine Combined with Chemotherapy in Treatment of Advanced Pancreatic Cancer

目的研究吉西他滨联合化疗在晚期胰腺癌治疗中的作用。方法本次研究对象均选自我院2017年5月至2019年5月收治的86例晚期胰腺癌患者,回顾分析患者临床资料,根据治疗方式分2组,其中参照组患者接受吉西他滨单药治疗,试验组患者则接受吉西他滨联合化疗治疗,就两种治疗方案在晚期胰腺癌治疗中的作用进行探讨。结果对比两组患者的疾病控制率、6个月生存率及临床受益反应,发现试验组患者的以上数据均显著优于参照组(P<0.05);对比两组患者的不良反应情况,发现试验组患者的不良反应率为48.84%,较参照组的41.86%略高,但并无统计学差异存在(P>0.05)。结论吉西他滨联合化疗治疗在晚期胰腺癌治疗中虽然不良反应率较高,但能够有效控制患者的病情,提升患者的生存率,延长患者的生存期,疗效较为显著,值得临床推广与应用。

Objective To study the effect of gemcitabine combined with chemotherapy in the treatment of advanced pancreatic cancer.Methods The subjects of this study were all selected from 86 patients with advanced pancreatic cancer admitted to our hospital from May 2017 to May 2019.The clinical data of the patients were retrospectively analyzed and divided into 2 groups according to the treatment methods.The patients in the reference group received gemcitabine monotherapy and the patients in the test group received gemcitabine combined chemotherapy.The roles of the two treatment schemes in the treatment of advanced pancreatic cancer were discussed.Results Comparing the disease control rate,6-month survival rate and clinical benefit response of the two groups,it was found that the above data of the patients in the test group were significantly better than those in the reference group(P<0.05).Comparing the adverse reactions of the two groups of patients,it was found that the adverse reaction rate of the patients in the test group was 48.84%,slightly higher than the 41.86%in the reference group,but there was no statistical difference(P>0.05).Conclusion Gemcitabine combined with chemotherapy in the treatment of advanced pancreatic cancer,although the adverse reaction rate is relatively high,can effectively control the patient’s condition,improve the survival rate of the patient,prolong the survival period of the patient,the curative effect is relatively significant,and is worthy of clinical promotion and application.